IAlternatives to ImmunoGen — ImmunoGen
Users exploring ImmunoGen alternatives often seek comparable biotechnology platforms specializing in targeted cancer therapies and antibody-drug conjugate development. Common motivations include evaluating different pipelines for oncology treatments, comparing clinical-stage assets, assessing partnership models with larger pharma, or identifying companies with similar innovation in ADC technology and monoclonal antibodies. Searchers may also compare regulatory progress, trial data transparency, manufacturing capabilities, or investment profiles when looking beyond ImmunoGen. Whether due to portfolio focus, geographic presence, or specific mechanism-of-action preferences, decision-makers review these options to find the best strategic or scientific fit for research collaborations, licensing, or competitive intelligence. This page highlights established players frequently considered alongside ImmunoGen.
Enhertu is AstraZeneca and Daiichi Sankyo's approved HER2-directed ADC used across multiple solid tumours. It offers strong clinical efficacy and a cleavable linker but relies on single-antigen targeting without logic gating. Compared with Valink Therapeutics, Enhertu has far greater clinical validation and commercial scale while Valink's V-Gate bispecific design seeks improved selectivity and resistance overcoming in earlier discovery stages.
Enhertu is AstraZeneca and Daiichi Sankyo's approved HER2-directed ADC used across multiple solid tumours. It offers strong clinical efficacy and a cleavable linker but relies on single-antigen targeting without logic gating. Compared with Valink Therapeutics, Enhertu has far greater clinical validation and commercial scale while Valink's V-Gate bispecific design seeks improved selectivity and resistance overcoming in earlier discovery stages.
Gilead Sciences (Kite Pharma)Trodelvy is Gilead's TROP-2 directed ADC approved for breast and urothelial cancers. It uses a moderately toxic payload and standard targeting. Versus Valink, Trodelvy provides real-world use data and broader indications today, whereas Valink's dual-target V-Gate approach aims for tighter tumour restriction and new payload opportunities not yet clinically tested.
AdcetrisAdcetris (brentuximab vedotin) from Seagen/Pfizer was one of the first approved ADCs targeting CD30 in lymphomas. It demonstrates durable responses but faces resistance issues common to single-target ADCs. Valink Therapeutics positions its bispecific V-Gate candidates as potential solutions for similar resistance mechanisms through multi-antigen logic in solid tumours where Adcetris is not indicated.
Roche VentanaPolivy is Roche's CD79b-targeted ADC approved for diffuse large B-cell lymphoma in combination regimens. It shows strong activity in hematologic malignancies. Valink focuses on solid tumour programs with continuous-level gating technology that Polivy lacks, targeting different biology and tissue distribution challenges.
BlenrepGSK's Blenrep is a BCMA-directed ADC for multiple myeloma that was later withdrawn in some markets due to safety concerns. Its experience highlights the need for improved selectivity. Valink's V-Gate platform is designed to enhance tumour-versus-healthy discrimination, potentially mitigating similar toxicity risks in future ADCs.
Mersana TherapeuticsMersana develops next-generation ADCs with novel payloads and linkers, including Dolasynthen and Immunosynthen platforms. Their work emphasises tolerability and new targets. Compared with Valink, Mersana has more disclosed clinical assets while Valink's LiliumX AI engine and V-Gate logic provide a differentiated discovery approach for bispecific constructs.
Sutro BiopharmaSutro uses cell-free expression to create homogeneous ADCs and bispecifics with precise conjugation. Their pipeline includes several oncology candidates. Valink similarly pursues bispecific ADCs but adds continuous-level gating and an integrated AI screening platform that Sutro's technology does not explicitly feature.
ZymeworksZymeworks develops multifunctional biotherapeutics including bispecific ADCs via its Azymetric and ZymeLink platforms. It has partnerships and clinical programs. Relative to Valink, Zymeworks offers more advanced clinical-stage bispecific assets while Valink emphasises AI-driven exploration of continuous-level gating logic for solid tumours.